The Department of Oncologic Pathology focuses on innovative discoveries and advances in research and clinical trials in cancer pathology that lead to the development of new care strategies and improved outcomes for patients.
The Department of Oncologic Pathology aids investigators throughout the organization in all disease areas as a hub for pathology resources. The Department also focuses on supporting precision medicine and immunotherapy — two of the Institute’s leading
research and patient care initiatives — and on developing preclinical models for cancer studies.
Massimo Loda, MD, is Chair of Dana-Farber’s Department of Oncologic Pathology. He received his MD degree summa cum laude from the University of Milan, Italy. He is a physician-scientist, professor of Pathology at Harvard Medical School, associate
member of the Broad Institute, and senior surgical pathologist at Brigham and Women’s Hospital.
Loda conceived, developed, and directs the state-of-the-art Molecular Pathology Core Laboratory at Dana-Farber. He is a pioneer molecular pathologist and has discovered and explored the mechanism of function of
several important cancer biomarkers. Loda’s laboratory has been focused for several years on metabolic alterations in prostate tumorigenesis, with a specific interest in lipid metabolism and its regulation.